Issues in selection of treatment regimen for multidrug-resistant tuberculosis

doi:10.3969/j.issn.1000-6621.2014.07.001

Abstract

TANG Shen-jie, LIU Yi-dian, ZHANG Zhan-jun, XIAO He-ping, WAN Li-ya. Issues in selection of treatment regimen for multidrug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2014, 36(7): 521-524. doi: 10.3969/j.issn.1000-6621.2014.07.001

References

［1］唐神结. 耐药结核病防治手册. 北京：人民卫生出版社，2009：75-156.
［2］唐神结，肖和平，张青. 耐多药结核病化疗研究的新进展.中华结核和呼吸杂志，2009，32（8）：617-620.
［3］中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告（2012）. 中国防痨杂志，2013，35（7）：488-510.
［4］中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告（2011）. 中国防痨杂志，2012，34（7）：463-471.
［5］Brigden G, Nyangwa BT, Cros P,et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organization,2014,92(1):68-74.
［6］World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis—2011 update. WHO/HTM/TB/2011.6.Geneva：World Health Organization, 2011.
［7］World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva：World Health Organization, 2008.
［8］肖和平. 耐药结核病化学治疗指南（2010年）.北京：人民卫生出版社，2011.
［9］Pierre-Audigier C，Surcouf C，Cadet-Daniel V，et al. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int J Tuberc Lung Dis，2012，16(2)：221-223.
［10］刘一典，唐神结，张青，等.上海地区结核分枝杆菌分离株对一线和二线抗结核药物的耐药性分析.中华传染病杂志，2011,29（9）：544-548.
［11］Tang SJ, Zhang Q, Zheng LH, et al. Efficacy and safety of linezolid for the treatment of extensively drug resistant tuberculosis. Jpn J Infect Dis,2011,64(6):509-512.
［12］姚岚，唐神结，肖和平，等.利奈唑胺治疗广泛耐药结核病的临床疗效观察. 中华临床医师杂志（电子版），2010，4（12）：2435-2440.
［13］Van Deun A，Maug AK，Salim MA，et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med，2010，182(5)：684-692.
［14］Laniado-Laborín R，Estrada-Guzman J，Perez H，et al. Treatment of multidrug-resistant tuberculosis in a high-prevalence region through a binational consortium. Int J Tuberc Lung Dis, 2012, 16(5)：610-611.
［15］Kliiman K，Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J,2009,33(5)：1085-1094.
［16］Cavanaugh JS，Kazennyy BY，Nguyen ML，et al. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002—2005.Int J Tuberc Lung Dis，2012，16(8)：1069-1074.
［17］World Health Organization. Definitions and reporting framework for tuberculosis—2013 revision. WHO/HTM/TB/2013.2. Geneva：World Health Organization, 2013.

[1]	Li Yang, Sun Feng, Zhang Wenhong. Short-course treatment for tuberculosis: past achievements and future directions [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 991-997.
[2]	Wang Xueyu, Shi Wenhui, Li Qi, Jing Wei, Chu Naihui, Nie Wenjuan. Efficacy and safety of Baidiziyin Pill and Shenqiyifei Pill in adjuvant treatment of susceptible pulmonary tuberculosis patients: a national randomized controlled multicenter clinical study [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1306-1312.
[3]	Fu Liang, Deng Guofang. MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 18-22.
[4]	Zhou Feng, Li Tongxin, Yang Song, Tang Shenjie. Progress on short-course regimens for the treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 311-317.
[5]	Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei. Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083.
[6]	Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao. Construction of pulmonary rehabilitation nursing program of integrated traditional Chinese and Western medicine for patients with tuberculous empyema under thoracoscopic clearance [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 932-939.
[7]	Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao. Analysis of the application effect of integrated traditional Chinese and Western medicine pulmonary rehabilitation nursing program for patients with tuberculous empyema undergoing thoracoscopic clearance [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 940-948.
[8]	Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910.
[9]	Jin Long, Wang Lihua, Zhang Xiaolei, Jiang Huailong, Li Xiaonan, Liu Yuqin. Efficacy and safety of modified all-oral short course chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1321-1326.
[10]	Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 859-866.
[11]	ZHOU Wen-qiang, ZHANG Shuang, CHU Nai-hui. Current status and prospect of all-oral treatment regimens for drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 879-882.
[12]	LIAO Wei-ming, FU Liang, DENG Guo-fang, YUAN Xiao-liang. Research progress of bedaquiline for the treatment of multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 619-624.
[13]	GE Qi-ping*, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334.
[14]	Shanghai Clinical Research Center for Infectious Disease (Tuberculosis)/Shanghai Pulmonary Hospital, Tongji University School of Medicine, Beijing Chest Hospital , Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the diagnosis and treatment of retreatment pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1226-1238.
[15]	HE Xiao-xin, LI Bo, ZHOU Lin. Interpretation of Four-month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1243-1247.